|
Author
|
Sample size (treatment group vs. control group)
|
Difference
|
95% CI
|
|---|
|
Cabral et al. [57]
|
32 (14 vs. 18)
|
− 1.07 mmol/L*
|
− 2.49 to 0.36
|
|
Caraccio et al. [58]
|
49 (24 vs. 25)
|
− 0.30 mmol/L*
|
− 0.92 to 0.32
|
|
Duman et al. [60]
|
39 (20 vs. 19)
|
0.00 mmol/L*
|
− 0.98 to 0.98
|
|
Iqbal et al. [62]
|
64 (32 vs. 32)
|
− 0.10 mmol/L*
|
− 0.59 to 0.39
|
|
Liu et al. [64]
|
119 (60 vs. 59)
|
− 0.29 mmol/L**
|
− 0.54 to − 0.04
|
|
Mikhail et al. [66]
|
120 (60 vs. 60)
|
− 0.30 mmol/L*
|
− 0.58 to − 0.30
|
|
Monzani et al. [68]
|
45 (23 vs. 22)
|
− 1.56 mmol/L*
|
− 2.91 to − 0.20
|
|
Nagasaki et al. [69]
|
95 (48 vs. 47)
|
− 0.14 mmol/L**
|
− 0.54 to 0.26
|
|
Teixeira et al. [74, 75]
|
26 (11 vs. 15)
|
− 0.32 mmol/L*
|
− 1.79 to 1.16
|
- *Value is the difference in mean scores at final follow-up between treatment and control groups
- **Value is the difference in mean variation scores from baseline to follow-up between treatment and control group
